PHARMACEUTICAL COMPOSITIONS OF FUNGICIDAL TRIAZOLE DERIVATIVES

Abstract: The disclosure relates to fungicidal pharmaceutical and veterinary compositions comprising as a fungicidally active ingredient a 1-(alkyl, cycloalkyl or optionally-substituted phenyl)-1-(optionally-substituted phenyl or benzyl)-2-(1,2,4-­ triazol-1-yl)-ethanol derivative, for example 1,1-bis(4-­ chlorophenyl)-2-(1,2,4-triazol-1-yl)ethanol, and a method of killing a micro-organism of the genus Candida or Trichophy­ ton by administering such a composition or triazole deriva­ tive to the locus of the micro-organism. The triazole deriva­ tives are formulated into the claimed compositions using conventional pharmaceutical excipients, and by convention­ al pharmaceutical techniques.

Description: TITLE: PHARMACEUTICAL COMPOSITIONS OF FUNGICIDAL TRIAZOLE DERIVATIVES This invention relates to pharmaceutical and veterinary compositions of fungicidal triazole derivatives, and in particular it relates to such compositions which are orally or topically active against fungus diseases of humans and other animals. The compositions of the invention are especially useful for treatment of candidiosis and human dermatophyte infections. Our co-pending European Patent Application Number 80300693.1 discloses a novel class of triazole derivatives of the general formula: EMI1.1 wherein R1 is alkyl, cycloalkyl or optionally substituted phenyl and R2 is optionally substituted phenyl or optionally substituted benzyl, and the acid addition salts and metal complexes thereof, and chemical processes for the manufacture of these compounds. The said patent application also discloses that these compounds and compositions containing them possess fungicidal activity, but the only such fungicidal activity which is exemplified therein is activity against fungus disease of plants. Similar compounds wherein R1 is phenyl substituted by an optionally-substituted phenyl or cycloalkyl group and R2 is an optionally-substituted phenyl or benzyl radical, are disclosed in prior European Patent Applications Numbers 11768 and 11769. The present invention therefore provides a pharmaceutical or veterinary fungicidal composition which comprises a triazole derivative of the formula II EMI2.1 wherein R3 is a 1-6C alkyl radical, a 4-7C cycloalkyl radical, a phenyl radical, a phenyl radical which is substituted by one or more substituents selected from halogen atoms and 1-5C alkyl, 1-4C alkoxy, 1-4C haloalkyl, 1-4C haloalkoxy, nitro, phenyl, phenoxy, benzyl, benzyloxy, halobenzyloxy, 1-4C alkylenedioxy, 1-4C haloalkylenedioxy, amino, 1-4C alkylamino, di(1-4C alkyl) amino, hydroxy, morpholino, carboxy and 2-5C alkoxycarbonyl radicals; and R4 is a phenyl or benzyl radical, or a phenyl or benzyl radical each substituted as defined above, or an acid addition salt thereof, but excluding compounds wherein R is a phenyl radical substituted by an optionallysubstituted phenyl or cycloalkyl radical and R4 is an optionally-substituted phenyl or benzyl radical, together with a pharmaceutically or veterinarily acceptable diluent or carrier. The compounds of the formula I contain a chiral centre when R and R4 are different. Such compounds are generally obtained in the form of racemic mixtures, but these can be separated into the individual isomers by methods known in the art, The alkyl radical R3 can be a straight or branched chain group, for example methyl, ethyl, propyl, (n- or iso-propyl) and butyl Cn-, sec- or t,-butyl) radicals, and preferred such alkyl radicals are those containing 1 to 4 carbon atoms. A suitable value for R1 when it is a cycloalkyl radical is, for example, a cyclopentyl or cyclohexyl radical. Examples of suitable substituents in the phenyl radical, R and R4, or in the phenyl moiety of the benzyl radical, R4, are fluorine, chlorine of bromine atoms, methyl, ethyl, propyl (n- or iso-propyl), butyl (n-, sec-, iso- or t-butyl), methoxy, ethoxy, trifluoromethyl, 1,1,2,2-tetrafluoroethyl, tIifluoromethoxy, 1,1,2,2tetrafluoroethoxy, chlorobenzyloxy, fluorobenzyloxy, methylenedioxy, 1,2-ethylenedioxy, 1 ,2-propylenedioxy, difluoromethylenedioxy, nitro, amino, methylamino, dimethylamino, hydroxy, morpholino, methoxycarbonyl and ethoxycarbonyl radicals. The alkyl moiety of the benzyl can be substituted with for example one alkyl (e.g. methyl or ethyl), so that R4 is a l-phenylethoxy or l-phenyl propoxy radical. Suitably the phenyl and benzyl are unsubstituted or substituted with 1, 2 or 3 ring substituents as defined above. Examples of these groups from which R may be selected are phenyl, 2-, 3- or 4chlorophenyl, 2,3- or 2,6-dichlorophenyl, 2-, 3- or 4fluorophenyl, 2,3- or 2,6-difluorophenyl, 2-, 3- or 4bromophenyl, 2-chloro-4-flu6rophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-6-fluorophenyl, 2-, 3- or 4-methoxyphenyl, 2,4-dimethoxyphenyl, 2-, 3- or 4-ethoxyphenyl, 2-, 3- or 4-nitrophenyl, 2-chloro-4-nitrophenyl, 2-chloro-5-nitrophenyl, 2-, 3- or 4-methylphenyl, 2,4-.dimethylphenyl, 2-, 3- or 4-t-butylphenyl, 2-, 3- or 4-trifluoromethylphenyl, 2-, 3- or 4-trifluoromethoxyphenyl, 2-, 3- or 4-(1,1,2,2- tetrafluoroethyllphenyl, 2,3- (ifluoromethylenedioxy) - phenyl, 2-fluoro-4-methoxyphenyl, 2-methoxy-4-fluoro phenyl, 2-methoxy-4-chlorophenyl, 2-, 3- or 4-phenoxyphenyl, 2-, 3- or 4-phenylphenyl (2-, 3- or 4biphenylyl), 2-, 3- or 4-benzylphenyl, 2-, 3- or 4benzyloxyphenyl, 2-, 3- or 4- (4-chloro- or 4-fluorobenzyloxy)phenyl, 2-, 3- or 4-aminophenyl, 2-, 3- or 4- (N,N-dimethylamino)phenyl, 2-, 3- or 4-aminophenyl, 2-, 3- or 4- (N,N-dimethylamino)phenyl, 2-, 3- or 4 hydroxyphenyl, 2-, 3- or 4-carboxyphenyl, 2-, 3- or 4-(methoxycarbonyl)phenyl and 2-, 3- or 4-morpholino phenyl and R4 may be selected from the same radicals, benzyl, &alpha;-methylbenzyl, and the corresponding ring substituted benzyl and &alpha;-methylbenzyl groups, bearing substituents as defined above in R . The salts can be salts with inorganic or organic acids e.g. hydrochloric, nitric, sulphuric, acetic, p-toluenesulphonic or maleic acid. Examples of compounds of the formula I, which may be used in the composition of the invention are shown 20 in the following Table I: TABLE I EMI5.1 <tb> Compound <SEP> R3 <SEP> R4 <SEP> Melting <tb> <SEP> Point <tb> <SEP> No. <SEP> ( C.) <tb> <SEP> 1 <SEP> C6H5- <SEP> C6H5CH2- <SEP> 124-125 <tb> <SEP> 2 <SEP> C6H5- <SEP> 4-Cl-C6H4CH20 <SEP> 144-145 <tb> <SEP> 3 <SEP> C6H5- <SEP> 4-F-C6H4CH2- <SEP> 116-118 <tb> <SEP> 4 <SEP> 4-Cl-C6H4- <SEP> 4-Cl-C6H4CH2- <SEP> 80-83 <tb> <SEP> 5 <SEP> 4-C1-C6H4- <SEP> C6H5CH2- <SEP> 109-111 <tb> <SEP> 6 <SEP> 4-F-C6H4- <SEP> C6H5CH20 <SEP> 141-142 <tb> <SEP> 7* <SEP> C6H5- <SEP> 2,4-Cl2-C6H3CH2- <SEP> 104-106 <tb> <SEP> 8+ <SEP> 4-F-C6H4- <SEP> 4-F-C6H4CH2- <SEP> 154-156 <tb> <SEP> 9 <SEP> 4-F-C <SEP> 6H4 <SEP> - <SEP> 4-Cl-C6H4CH2- <SEP> 168-170 <tb> <SEP> 10 <SEP> t-Bu <SEP> @ <SEP> C6H5CH2- <SEP> 110-111 <tb> <SEP> 11 <SEP> t-Bu <SEP> 4-Cl-C6H4CH2- <SEP> 86-87 <tb> <SEP> 12 <SEP> t-Bu <SEP> 4-F-C6H4CH2- <SEP> 146-148 <tb> <SEP> 13 <SEP> C6H5- <SEP> 2-F-C6H4CH2- <SEP> 133-134 <tb> <SEP> 14 <SEP> 4-Cl-C6H4- <SEP> 2-F-C6H4CH2- <SEP> 95-96 <tb> <SEP> 15 <SEP> C6H5- <SEP> 2-Cl-C6H4CH2- <SEP> 69-71 <tb> <SEP> 16 <SEP> 4-MeO-C <SEP> H <SEP> - <SEP> C6H5CH2- <SEP> 100-103 <tb> <SEP> 17 <SEP> C6H5- <SEP> C6H5- <SEP> 128-129 <tb> <SEP> 18+ <SEP> 4-F-C6H4- <SEP> 3-F-C6H4CH2- <SEP> 161-163 <tb> <SEP> 19 <SEP> C6H5- <SEP> 2,4-C12-C6H3CH2- <SEP> 104-106 <tb> <SEP> 20 <SEP> t-Bu <SEP> 2-Cl-C <SEP> H <SEP> CH2 <SEP> - <SEP> <SEP> 74-75 <tb> <SEP> 21 <SEP> t-Bu <SEP> 2-F-C6H4CH2 <SEP> 96-98 <tb> <SEP> 22 <SEP> t-Bu <SEP> 3-Cl-C6H4CH2- <SEP> 88-89 <tb> <SEP> 23 <SEP> t-Bu <SEP> 3-CF3-C6H4CH2 <SEP> - <SEP> 106-107 <SEP> <tb> <SEP> 24 <SEP> C6H5- <SEP> 4-t-Bu-C6H4CH2- <SEP> 80-83 <tb> <SEP> 25 <SEP> 4-C1-C6H4- <SEP> C6H5- <SEP> 83-85 <tb> <SEP> 26 <SEP> 4-C1-C6H4- <SEP> 4-C1-C6H4- <SEP> 147-148 <tb> <SEP> 27 <SEP> 4-Cl-C6H4- <SEP> 4-F-C6H4- <SEP> 154-155 <tb> <SEP> 28 <SEP> 2,4-diCl-C6H3- <SEP> C6H5- <SEP> 191-194 <tb> <SEP> 29 <SEP> 4-F-C6H4- <SEP> 4-F-C6H4- <SEP> 170-171 <tb> <SEP> 30 <SEP> 4-F-C6H4- <SEP> C6H5- <SEP> 139-140 <tb> <SEP> 31 <SEP> i-Bu <SEP> C6H5- <SEP> 94-95 <tb> <SEP> 32 <SEP> n-Bu <SEP> 4-C1-C6H5- <SEP> 95-97 <tb> TABLE I (continued) EMI6.1 <tb> Compounds <SEP> R <SEP> R4 <SEP> Melting <tb> <SEP> No. <SEP> Point <SEP> <tb> <SEP> 33 <SEP> t-Bu <SEP> 2-F-4-Cl-C2H2CH3- <SEP> 95 <tb> <SEP> 34 <SEP> t-Bu <SEP> 2-F-4-C1-C6H3CH2- <SEP> 104-106 <tb> <SEP> 35 <SEP> C6H5- <SEP> 4-t--Bu-C6H4- <SEP> 131-135 <tb> <SEP> 36 <SEP> 4-Cl-C2H4- <SEP> 2-C1-C <SEP> H <SEP> - <SEP> 137-138 <tb> <SEP> 37 <SEP> 4-Cl-C6H4- <SEP> 2-F-C6H4- <SEP> 144-145 <tb> <SEP> 38 <SEP> 4-F-C6H4 <SEP> - <SEP> 2-F-C6H4- <SEP> 115-116 <SEP> <tb> 39 <SEP> 3-F-C6H4- <SEP> 2-F-C6H4 <SEP> 120-123 <tb> <SEP> 40 <SEP> 4-Cl-C6H4- <SEP> 2-Me-C6H- <SEP> 157-158 <tb> <SEP> 41 <SEP> 2,4-C12-C6H3- <SEP> 4-F-C6H4- <SEP> 137-138 <tb> <SEP> 42 <SEP> 2-Cl-C6H4- <SEP> 4-MeO-C6H4- <SEP> 184-185 <tb> <SEP> 43 <SEP> 2,4-diCl-C6H3- <SEP> 4-C1-C6H4- <SEP> 174-175 <tb> <SEP> 44 <SEP> 2,3-diCl-C6H3- <SEP> 2-FlC6H4- <SEP> 149-151 <tb> <SEP> 45 <SEP> 2,3-diCl-C6H3- <SEP> 2-F1C6H4- <SEP> 146-147 <tb> <SEP> 46 <SEP> 4-Cl-C6H4CH2O)- <SEP> C6H5- <SEP> 134-136 <tb> <SEP> 47 <SEP> 4-(4-Cl-C6H4CH2O)- <SEP> C6H5- <SEP> 98-100 <tb> <SEP> C6H4 <SEP> - <SEP> <tb> <SEP> 48 <SEP> 3-Cl-C6H4- <SEP> 4-Cl-C6H4- <SEP> 139-142 <tb> <SEP> 49 <SEP> 4-(4-F-C6H4CH2O)- <SEP> C6H5- <SEP> 105-107 <tb> <SEP> C6H4 <tb> <SEP> 50 <SEP> 3-Cl-C6H4- <SEP> 4-F-C6H4- <SEP> 190-193 <tb> <SEP> 51 <SEP> 3-C1-C6H4- <SEP> 4-MeS-C6H4- <SEP> 58-60 <tb> <SEP> 52 <SEP> 2,4 <SEP> C12 <SEP> 6 <SEP> 3 <SEP> 3-C1-C6H4- <SEP> 139-142 <tb> <SEP> 53 <SEP> 2-Me-C6H4- <SEP> 4-F-C6H4- <SEP> 200-201 <tb> <SEP> 54 <SEP> 2-Me-C6H4- <SEP> 4-C1-C6H4- <SEP> 157-158 <tb> <SEP> 55 <SEP> t-Bu <SEP> <RTI ID=6.10> 4-Br-C6H4CH2- <SEP> 111-115 <tb> <SEP> 56 <SEP> t-Bu <SEP> 2,4-F2-C6H3CH2- <SEP> 140 <tb> <SEP> 57 <SEP> t-Bu <SEP> 2-Cl-C6H4- <SEP> 113-116 <tb> <SEP> 58 <SEP> C6H5- <SEP> 2-F-C6H4- <SEP> 142-143 <tb> <SEP> 59 <SEP> C6H5- <SEP> 2-F-C6H4- <SEP> 126-128 <tb> <SEP> 6- <SEP> C6H5- <SEP> 2-Me-C6H4- <SEP> 161-162 <tb> <SEP> 61 <SEP> 4-F-C6H4- <SEP> 4-MeO2C-C6H4 <SEP> 126-127 <SEP> <tb> <SEP> 62 <SEP> 4-BtO-C6H4- <SEP> 4-Cl-C6H4- <SEP> 126-127 <tb> 63 <SEP> 4-CF2H.O-C6H4 <SEP> 4-C1-C6H4- <SEP> glass <tb> TABLE I (continued) EMI7.1 <tb> Compounds <SEP> 3 <SEP> 4 <SEP> <SEP> Melting <tb> <SEP> No. <SEP> R <SEP> R <SEP> <SEP> Point <tb> <SEP> 64 <SEP> 4-CF2H4O-C6H4- <SEP> 2-Cl-C6H4- <SEP> glass <tb> <SEP> 65 <SEP> 2-Br-C6H4- <SEP> 4-C1-C6H4- <SEP> 151-152 <tb> <SEP> 66 <SEP> 2-Br-C6H4- <SEP> 4-F-C6H4- <SEP> 109-111 <tb> <SEP> -67 <SEP> 4-N02-C6H4- <SEP> C6H5 <SEP> 164-166 <tb> <SEP> 68 <SEP> 2-Cl-5-N02-C6H3- <SEP> C6H5 <SEP> 206-208 <tb> <SEP> 69 <SEP> 4-Me-C6H4- <SEP> C6H5 <SEP> 125-127 <tb> <SEP> 70 <SEP> 2-MeO-C6H4- <SEP> C6H5 <SEP> 113-116 <tb> <SEP> 71 <SEP> 2-MeO-C6H4- <SEP> 4-C1-C6H4- <SEP> 129-131 <tb> <SEP> 72 <SEP> 2-MeO-C6H4- <SEP> 4-F-C6H4- <SEP> 133-135 <tb> <SEP> 73 <SEP> 4-Br-C6H4- <SEP> C6}35- <SEP> 104-105 <tb> <SEP> 74 <SEP> 4-Br-C6H4- <SEP> 4-Br-C6H4- <SEP> 159-160 <tb> <SEP> 75 <SEP> 4-Br-C6H4- <SEP> 4-Cl-C6H4- <SEP> 138-139 <tb> <SEP> 76 <SEP> 2-Me-C6H4- <SEP> 4-Me-C6H4- <SEP> 117-120 <tb> <SEP> 77 <SEP> 2-C1-C6H4- <SEP> 4-Me-C6H4- <SEP> 169-170 <tb> <SEP> 78 <SEP> 2-F-C6H4- <SEP> 4-Me-C6H4- <SEP> 156-158 <tb> <SEP> 79 <SEP> 4-F-C6H4- <SEP> 4-N02-C6H4- <SEP> 145-148 <tb> <SEP> 80 <SEP> 4-Me-C6H4- <SEP> 4-Me-C6H4- <SEP> 153-154** <SEP> <tb> <SEP> 81 <SEP> 3-N02-C6H4- <SEP> C6H5- <SEP> 212-215** <SEP> <tb> <SEP> 82 <SEP> 2-Cl-C6H4- <SEP> 2-Cl-C6H4- <SEP> 164-166 <tb> <SEP> 83 <SEP> 3-CF3-C6H4- <SEP> C6H5 <SEP> - <SEP> <SEP> 115-117 <tb> <SEP> 84 <SEP> 4-CF4-C6H4- <SEP> C6H5- <SEP> 207-210** <tb> <SEP> 85 <SEP> 3-CF3-C6H4- <SEP> 4-C1-C6H4- <SEP> 104-106 <tb> <SEP> 86 <SEP> 4-CF3O-C6H4 <SEP> C6H5 <SEP> glass <tb> <SEP> 87 <SEP> 4-CF3O-C6H4- <SEP> 4-C1-C6H4- <SEP> 107-108 <tb> <SEP> 88 <SEP> 4-CF#O-C6H4- <SEP> <SEP> 2-Cl-C6H4 <SEP> 99-100 <tb> <SEP> 89 <SEP> 2-CF2H.CF2O-C6H4- <SEP> C6H5 <SEP> 188-189 <tb> <SEP> 90 <SEP> 2-CF2H.CF2O-C6H4- <SEP> 4-Cl-C6H4- <SEP> 94-95 <tb> <SEP> 91 <SEP> 4-CF2H.CF2O-C6H4- <SEP> C6H5 <SEP> glass <tb> <SEP> 92 <SEP> 4-CF2H.CF2O-C6H4- <SEP> 4-CF2H.CF2O-C6H4- <SEP> glass <tb> <SEP> 93 <SEP> 4-CF2H.CF20-C6H4 <SEP> 4-C1-C6H4- <SEP> glass <tb> <SEP> 94 <SEP> Et <SEP> C6H5 <SEP> 96-97 <tb> <SEP> 95 <SEP> Et <SEP> 4-C1-C6H4- <SEP> 105-106 <tb> TABLE I (continued) EMI8.1 <tb> Compounds <SEP> R <SEP> R4 <SEP> Melting <tb> <SEP> No. <SEP> Point <tb> <SEP> 96 <SEP> Et <SEP> 4-F-C6H4- <SEP> 94 <tb> <SEP> 97 <SEP> n-Pr <SEP> C6H5 <SEP> 77-79 <tb> <SEP> 98 <SEP> cyclo-Pr <SEP> C6H5 <SEP> 91-92 <tb> <SEP> 99 <SEP> cyclo-Pr <SEP> 4-C1-C6H4- <SEP> oil <tb> <SEP> 100 <SEP> cyclo-Pr <SEP> 4-MeO-C6H4- <SEP> 101-102 <tb> <SEP> 101 <SEP> n-Bu <SEP> C6H5- <SEP> 62-63 <tb> <SEP> 102 <SEP> n-Bu <SEP> 4-F-C6H4- <SEP> 93-95 <tb> <SEP> 103 <SEP> n-Bu <SEP> 2,4-C12-C6H3- <SEP> 106-108 <tb> <SEP> 104 <SEP> t-Bu <SEP> C6H5- <SEP> 75 <tb> <SEP> 105 <SEP> t-Bu <SEP> 4-C1-C6H4- <SEP> 70-73 <tb> <SEP> 106 <SEP> t-Bu <SEP> 4-F-C6H4- <SEP> 92-93 <tb> <SEP> 107 <SEP> t-Bu <SEP> 4-MeO-C6H4- <SEP> 48 <tb> <SEP> 108 <SEP> n-C6H13 <SEP> 4-F-C6H4- <SEP> 97-99 <tb> <SEP> 109 <SEP> cyclohexyl <SEP> C6H5- <SEP> 110-111 <tb> <SEP> 110 <SEP> cyclohexyl <SEP> 4-C1-C6H4- <SEP> 45 <tb> <SEP> 111 <SEP> cyclohexyl <SEP> 4-MeO-C6H4- <SEP> 92-94 <tb> <SEP> 112 <SEP> t-Bu <SEP> 4-MeO-C6H4. <SEP> CH2- <SEP> 130-131 <SEP> <tb> <SEP> 113 <SEP> 4-Cl-3-N02-C63 <SEP> - <SEP> C6H5- <SEP> 139-141 <tb> <SEP> 114 <SEP> 3-C1-C6H4- <SEP> C6H5 <SEP> - <SEP> <SEP> 108-110 <tb> <SEP> 115 <SEP> 3-F-C6 <SEP> H4- <SEP> 4-C1-C6H4- <SEP> 55-59 <tb> <SEP> 116 <SEP> 3-F-C6H4- <SEP> 4-F-C6H4 <SEP> - <SEP> 116-118 <tb> <SEP> 117 <SEP> 4-MeO-C6H4- <SEP> C6H5- <SEP> 88-89 <tb> <SEP> 118 <SEP> 4-PhO-C6H4- <SEP> C6H5 <SEP> - <SEP> 103-105 <tb> <SEP> 119 <SEP> 2-MeO-C6H4- <SEP> 4-MeO-C6H4- <SEP> 133-134 <tb> <SEP> 120 <SEP> 2-F-C6H4- <SEP> 4-MeO-C6H4- <SEP> 144-145 <tb> <SEP> 121 <SEP> 4-NO <SEP> -C6H <SEP> - <SEP> 4-Cl-C6H4 <SEP> 157-158 <tb> <SEP> 122 <SEP> 4-Me0-C6H4- <SEP> 4-Cl-C6H4- <SEP> 105-106 <tb> <SEP> 123 <SEP> 4-PhO-C6H4- <SEP> 2-Cl-C6H4- <SEP> 100-102 <tb> <SEP> 124 <SEP> 4-PhO-C6H4- <SEP> 2-FlC6H4- <SEP> 132-133 <tb> <SEP> 125 <SEP> 2,4-Cl2-C6H3- <SEP> 4-MeO-C6H4- <SEP> 178-180 <tb> <SEP> 126 <SEP> 4-MeO-C6H4- <SEP> 4-F-C6H4- <SEP> 124-125 <tb> <SEP> 127 <SEP> 4-CF2H.CF2O-C6H4- <SEP> 2,4-C12C6H3- <SEP> 125-126 <tb> <SEP> 128 <SEP> 4-MeO2C-C6H4- <SEP> C6H5- <SEP> 70-72 <tb> TABLE I (continued) EMI9.1 <tb> Compounds <SEP> 3 <SEP> 4 <SEP> <SEP> Melting <tb> <SEP> No. <SEP> R <SEP> R <SEP> Point <tb> <SEP> @ <tb> <SEP> 129 <SEP> 4-CN-C6H4- <SEP> C6H5- <SEP> 82-85 <tb> <SEP> 130 <SEP> 4-Me-C6H4- <SEP> 4-Cl-C6H4- <SEP> 134-135 <tb> <SEP> 131 <SEP> 4-Me-C6H4- <SEP> 4-F-C6H4- <SEP> 124-125 <tb> <SEP> 132 <SEP> 2-MeO-C6H <SEP> - <SEP> 2,4-C12-C6H3- <SEP> 152-153 <tb> <SEP> 133 <SEP> 3-PhO-C6H4- <SEP> 4-Cl-C6H4- <SEP> 177-178* <tb> <SEP> 134 <SEP> 4-PhO-C6H4 <SEP> - <SEP> 4-F-C6H4- <SEP> <SEP> 138-140 <tb> <SEP> 135 <SEP> 4-i-PrO-C6H4- <SEP> 4-C1-C6H4- <SEP> 151-153 <tb> <SEP> 136 <SEP> n-Bu <SEP> 4-Me-C6H4- <SEP> 80-81 <tb> <SEP> 137 <SEP> n-C6H13- <SEP> 4-Me-C6H4- <SEP> 76-78 <tb> <SEP> 138 <SEP> 4-CF3O-C6H4- <SEP> 2-F-C6H4- <SEP> glass <tb> <SEP> 139 <SEP> 4-CF30-C6H4- <SEP> 4-F-C6H4- <SEP> 132-133 <tb> <SEP> 140 <SEP> 4-CF3O-C6H4 <SEP> - <SEP> 2-MeO-C6H <SEP> - <SEP> 115-116 <tb> <SEP> 141 <SEP> 2-CF2H-O-C6H4 <SEP> 2-C1-C6H <SEP> - <SEP> 114-115 <tb> <SEP> 142 <SEP> 2-CF2H.CF2O-C6H4- <SEP> 4-F-C6H4- <SEP> 115-116 <tb> <SEP> 143 <SEP> 4-CF2H.CF20-C6H4- <SEP> 4-F-C6H4- <SEP> 125-126 <tb> <SEP> 144 <SEP> 4-CF2H.CF2O-C6H4- <SEP> 2-F-C6H4- <SEP> 110-111 <tb> <SEP> 145 <SEP> 3,4-methylenedioxy <tb> <SEP> C6H3- <SEP> 4-Cl-C6H4- <SEP> 129-130 <tb> <SEP> 146 <SEP> 2-C1-C6H4- <SEP> 4-EtO-C6H4- <SEP> 94-96 <tb> <SEP> 147 <SEP> 2,4-Cl2-C6H3- <SEP> 4-EtO-C6H4- <SEP> 159-161 <tb> <SEP> 148 <SEP> 4-C1-C6H4- <SEP> 4-NYH2-C6H4- <SEP> 56 <tb> <SEP> 149 <SEP> 4-Cl-C6H4- <SEP> 4-AcNH-C6H4- <SEP> 70-75 <tb> <SEP> 150 <SEP> 4-C1-C6H4- <SEP> 4-CN-C6H4 <SEP> - <SEP> 160 <tb> <SEP> 151 <SEP> 4-F-C6H4 <SEP> - <SEP> 4-CN-C6H4- <SEP> 139-140 <tb> <SEP> 152 <SEP> 4-Me-C6H4- <SEP> 2,4-C12-C6H3- <SEP> 183 <tb> <SEP> 153 <SEP> 2-Cl-C6H4- <SEP> 2-MeO-C6H <SEP> - <SEP> 148-150 <tb> <SEP> 154 <SEP> 4-CN-C5H4- <SEP> 2,4-Cl2-C6H3- <SEP> 182-184 <tb> <SEP> 155 <SEP> 2-F-4-MeO-C6H3- <SEP> 4-F-C6H4 <SEP> - <SEP> 161-162 <tb> <SEP> 156 <SEP> 2-Cl-4-MeO-C6H3- <SEP> 4-F-C6H4- <SEP> 138-140 <tb> <SEP> 157 <SEP> 2-Cl-4-MeO-C6H3- <SEP> 4-C1-C6H4- <SEP> 176-177 <tb> <SEP> 158 <SEP> 2-F-MeO-C6H3- <SEP> 2-C1-C6H <SEP> - <SEP> 170-172 <tb> <SEP> 159 <SEP> 2-F-MeO-C6H3- <SEP> 4-C1-C6H4 <SEP> - <SEP> 134-136 <tb> <SEP> 160 <SEP> 2-Cl-4-Me-C6H3- <SEP> 4-F-C6H4- <SEP> 158 <tb> TABLE I (continued) EMI10.1 <tb> <SEP> ! <SEP> <tb> Compounds <SEP> R3 <SEP> R4 <SEP> Point <tb> <SEP> No. <SEP> t C.) <SEP> <tb> <SEP> 161 <SEP> 4-Cl-2-Me-C6H3- <SEP> 4-F-C6H4- <SEP> 65-67 <tb> <SEP> 162 <SEP> 4-Cl-3-Me-C6H3- <SEP> 4-Cl-C6H4- <SEP> 175-176 <tb> <SEP> 163 <SEP> cyclobutyl <SEP> C6H5 <SEP> - <SEP> <SEP> oil <tb> <SEP> 164 <SEP> 2,4-C12-C6H3- <SEP> 2,4-Cl2-C6H3- <SEP> 170 <tb> <SEP> 165 <SEP> 3-NO2-C6H4- <SEP> 3-NO2-C6H4- <SEP> 170-172 <tb> * Includes 1 mole of ethanol occluded in the crystal lattice + Compounds 8 and 18 were obtained as polymorphs and this explains their different melting points. ** Hydrochloride salt The composition of the invention may be in a conventional pharmaceutical form suitable for oral administration, for example a tablet, a capsule, an emulsion or an aqueous or oily solution or suspension, or suitable for topical application, for example a cream, ointment or gel. The composition may contain conventional pharmaceutical excipients, and may be manufactured by conventional pharmaceutical techniques. Preferred pharmaceutical or veterinary compositions of the invention are compositions suitable for oral administration, and particularly tablets and capsules. European Patent Application No. 80300693.1 referred to above also discloses fungicidal compositions comprising a triazole derivative of the formula I in admixture with an inert carrier or diluent, for example kaolin, bentonite, kieselguhr, dolomite, calcium carbonate, talc, powdered magnesia, Fuller's earth, etc., and optionally including also wetting agents or suspending agents. We have now discovered that a selection of said fungicidal compositions is particularly useful for the treatment of candidosis and human dermatophyte infections. Thus, according to a further feature of the invention there is provided a fungicidal composition for-pharmaceutical -or veterinary use which comprises a triazole derivative of the formula: EMI11.1 wherein R5 and R6, which may be the same or different, are each a phenyl radical bearing a halogen substituent in the 4-position, or a salt thereof, and an inert carrier or diluent. It is to be understood that the phenyl radicals R5 and R6 may also bear other substituents, in addition to the halogen substituent in the 4-position, as defined in European Patent Application Number 80300693.1, referred to above, and other halogen substituents are preferred. Suitable halogen substituents, in the 4-position of R5 and P6, or as additional substituents in other positions of R5 and R6 are, for example, chlorine, fluorine and bromine atome. Suitable optional other substitutents in R5 and R6, in addition to the halogen substituents in the 4positions, are, for example, nitro, cyano, 1-SC alkyl, 1-4C alkoxy, 1-4C halogenoalkyl and 1-4C halogenoalkoxy, for example methyl, ethyl, propyl - or isopropyl), butyl (n-, sec-, iso- and t-butyl), methoxy, ethoxy, propoxy Cn- and isopropoxy), butoxy ±n-, sec-, isoand t-butoxy), trifluoromethyl, trichloromethyl, difluoromethyl, dichloromethyl, difluoromethoxy, trifluoromethoxy, 1,1,2, 2-tetrafluoroethoxy, pentafluoroethoxy and trifluoroethoxy radicals. The salts can be salts with inorganic or organic acids, for example hydrochloric, nitric, sulphuric acetic, toluene-p-sulphonic, maleic, tartaric or citric acids. Examples of particular preferred compounds of the formula III which may be used in the fungicidal composition are those numbered 26, 27, 29, 41, 43, 74, 75, 161, 162 and 164 in Table I. We have further discovered that, within this class of fungicidal compositions containing as active ingredient a triazole derivative of the formula II as defined above, and which are particularly useful for the treatment of candidosis and human dermatophyte infections, the selection of the compound l-(2,4-dichlorophenyl)-l (4-fluorophenyl)-2- (1,2, 4-triazol-1-yl)ethanol confers especially valuable advantages in terms of high in vivo fungicidal activity against Candida and Trichophyton species, and freedom from undesired side effects. Thus, according to a further feature of the invention there is provided a fungicidal composition which comprises l-(2,4-dichlorophenyl}-1-(4-fluorophenyl)- 2-(1,2,4-triazol-1-yllethanol or a salt thereof, and an inert carrier or diluent. The antifungal activity of the active ingredients of the compositions of the invention against Candida albicans, a causative fungus of candidosis and Trichlorophyton mentagrophytes, var. quinkeanum, was demonstrated as follows: Female mice of around 30g. weight are injected sub-cutaneously on a Friday with 0.5mg. of oestradiol benzoate. The following Monday (day 0) they are clipped on the back and then dosed orally with test compounds. They are then inoculated with Candida albicans in the vagina and Trichophyton mentagrophytes var. auinkeanum on the back, and then given a second dose of the same compound. Dosing is repeated once daily on days 1-4. On day 7 skin lesions are scored visually and vaginal samples taken for culture on agar. Groups of 5 mice are used and compounds are dosed initially at a level of 250mg./kg. The dose is then reduced sequentially until a minimum effective dose (MED) is found. The following table shows minimum effective doses (mg./kg.) giving complete control of infection, for a representative selection of triazole derivatives of the formula II: EMI13.1 EMI13.2 <tb> No. <SEP> in <SEP> R2 <SEP> R3 <SEP> MED <SEP> v. <SEP> MED <SEP> v, <tb> Table <SEP> I <SEP> C. <SEP> alibicans <SEP> T.mentagro- <SEP> <tb> <SEP> phytes, <SEP> var. <tb> <SEP> quinkeanum <tb> <SEP> 25 <SEP> 4-CI-phenyl <SEP> phenyl <SEP> 50 <SEP> 50 <tb> <SEP> 39 <SEP> 4-F-phenyl <SEP> 2-F-phenyl <SEP> 50 <SEP> 50 <tb> EMI14.1 <tb> No. <SEP> in <SEP> R2 <SEP> R3 <SEP> MED <SEP> s. <SEP> MED <SEP> V. <tb> Table <SEP> I <SEP> 'c. <SEP> alibi-cans <SEP> T.mentagro <tb> <SEP> phytes, <SEP> var. <tb> <SEP> I <SEP> quinkeanum <tb> <SEP> 37 <SEP> 4-Cl-phenyl <SEP> 2-.F-phenyl <SEP> 25 <SEP> 25 <tb> <SEP> 26 <SEP> 4-Cl-phenyl <SEP> 4-Cl-phenyl <SEP> 10 <SEP> 10 <tb> <SEP> 38 <SEP> 2-Cl-phenyl <SEP> 4-F-phenyl <SEP> 50 <SEP> 25 <tb> <SEP> 36 <SEP> 2-Cl-phenyl <SEP> 4-Cl-phenyl <SEP> 25 <SEP> 25 <tb> <SEP> 27 <SEP> 4-Cl-phenyl <SEP> 4-F-phenyl <SEP> 5 <SEP> 5 <tb> <SEP> 29 <SEP> 4-F-phenyl <SEP> 4-F-phenyl <SEP> 5 <SEP> 5 <tb> <SEP> 41 <SEP> 2,4-diCl-phenyl <SEP> 4-Flphenyl <SEP> 5 <SEP> 5 <tb> Thus, according to a further feature of the invention, there is provided a method of killing a micro-organism of the genus Candida or Trichophyton which comprises administering a compound of the formula II as defined above, or a composition of the invention, to the locus of said micro-organism. The invention is illustrated but not limited by the following Examples, in which "parts" are by weight: Example 1 A mixture of 5, 10, 25, 50, 100 or 250 parts of l-(2,4-dichlorophenyl)-1-(4-fluorophenyl)-2-(1,2,4- triazol-l-yllethanol with 70 parts of calcium carbonate and 200 parts of a 10% maize starch paste is dried and then passed through a 16 mesh screen. 5 parts of magnesium stearate are added and the granules are compressed to give a range of tablets suitable for oral administration for therapeutic purposes. This active ingredient may be replaced by a therateutically equivalent amount of any other triazole derivative as hereinbefore defined. Example 2 A mixture of 2, 5, 10, 25, 50 or 100 parts of 1- (2, 4-dichlorophenyl) -1- (4-fluorophenyl) -2-Cl, 2,4- triazol-l-yl)ethanol, 500 parts of lactose and 100 parts of maize starch is treated with sufficient 10% maize starch paste to give a granular mass. The mixture is passed through a 16-mesh screen, dried, mixed with 8 parts of magnesium stearate and compressed into tablets, giving a range of tablets suitable for oral administration for therapeutic purposes. The active ingredient may be replaced by a therapeutically equivalent amount of any other triazole derivative as hereinifore defined. Example 3 A mixture of 10 parts of l-(2,4-dichlorophenyl)- 1- (4-fluorophenyl)-2- (l,2,4-triazol-l-yl) ethanol and 190 parts of wheat germ oil is filled into soft gelatin capsules, to give capsules suitable for oral administration for therapeutic purposes. The active ingredient may be replaced by a therapeutically equivalent amount of any other triazole derivative as hereinbefore defined. Example 4 A solution of 10 parts of l-(2,4-dichlorophenyl)- 1-(4-fluorophenyll-2-(1,2,4-triazol-1-yl)ethanol in 83 parts of water, 250 parts of glycerol and 125 parts of ethyl alcohol is mixed with a solution of 300 parts cf sucrose in 150 parts of water. A suitable flavouring agent and colouring matter are then added to produce a syrup suitable for oral administration for therapeutic purposes. The active ingredient may be replaced by a therapeutically equivalent amount of any other triazole derivative as hereS9Ffore defined. Example 5 A mixture of 3 parts of gum acacia and 1.5 parts of gum tragacanth is added to a mixture of I part of l-(2,4-dichlorophenyl)-1-(4-fluorophenyl)-2-(1,2,4- triazol-l-yl)ethanol and 33.7 parts of liquid paraffin. To the thoroughly triturated mixture is added slowly with stirring a solution of 0.1 part of cetyl alcoholpolyoxyethylene condensate, 40 parts of sucrose, 0.03 part of propyl p-hydroxybenzoate, 0.3 parts of methyl c- hydroxybenzoate, a suitable flavouring agent and 0.002 part of edible dyestuff in 110 parts of water. The mixture is then homogenized in conventional manner known in the art to produce an emulsion suitable for oral administration for therapeutic purposes. The active ingredient may be replaced by a therapeutically equivalent amount of any other triazole derivative as hereinbefore defined. Example 6 A mixture of 0.5 part of finely divided 1-(2,4 dichlorophenyl) -1- (4-fluorophenyl) -2- (l,2,4-triazo2 -1- yl)ethanol in 3 parts of propylene glycol and 2 parts of ethylene glycol monoethyl ether was added to a stirred mixture of 4 parts of a lanolin and 90.5 parts of molten soft white paraffin. The resulting mixture was allowed to cool to room temperature with rapid stirring, to give a uniform ointment containing 0.5% by weight of active ingredient suitable for topical administration for therapeutic purposes The active ingredient may be replaced by another triazole derivative as hereinbefore defined to give similar ointments. Example 7 A solution was prepared of 1 part of 1-(2,4- dichlorophenyl)-l- (4-fluorophenyl)-2- ±l,2,4-triazol-l- yl)-ethanol in 20 parts of ethanol and 27 parts of diethylene glycol monethyl ether, then 50 parts of purified water was added, followed by 2 parts of a carboxypolymethylene gelling agent ("Carbapol 940" - trade mark) to give a finely dispersed gel suitable for topical administration for therapeutic purposes. The active ingredient may be replaced by any other triazole derivative as hereinbefore described.

Claims: What we claim is: 1. A pharmaceutical or veterinary fungicidal composition which comprises a triazole derivative of the formula: EMI18.1 P3 is a l-6C alkyl radical, wherein R is a 1-6C alkyl radical, a -7C cycloalkyl radical, a phenyl radical a phenyl radical which is substituted by one or more substituents selected from halogen atoms and 1-5C alkyl, 1-4C alkoxy, 1-4C haloalkyl, 1-4C haloalkoxy, nitro, phenyl, phenoxy, benzyl, benzyloxy, halobenzyloxy, 1-4C aikylenedioxy, 1-4C haloalkylenedioxy, amino, 1-4C alkylamino, di(l-4C alkyl)amino, hydroxy, morpholino, carboxy and 2-5C alkcxycarbonyl radicals; and R4 is a phenyl or benzyl radical, or a phenyl or benzyl radical each substituted as defined above, or an acid addition salt thereof, but excluding compounds herein R is a phenyl radical substituted by an optionally-substituted phenyl or cycloalkyl radical and R4 is an optionally-substituted phenyl or benzyl radical, together with a pharmaceutically or veterinarily acceptable diluent or carrier. 2. A composition as claimed in claim 1 wherein, in the triazole derivative, R is a methyl, ethyl, propyl (n- or iso-propyl), butyl (n-, sec-, iso- or t-butyl), cyclopentyl, cyclohexyl, phenyl or phenyl substituted by one or more substituents selected from fluorine, chlorine and bromine atoms and methyl, ethyl, propyl (n- or isopropyl), butyl (n-, sec-, iso- and t-butyl), methoxy1 ethoxy, trifluoromethyl, 1,1,2,2-tetrafluoroethyl, trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy, chlorobenzyl oxy, fluorobenzyloxy, methylenedioxy, 1, 2-ethylenedioxy, 1, 2-propylenedioxy, difluoromethylenedioxy, nitro, amino, methylamino, dimethylamino, methoxycarbonyl and ethoxycarbonyl radicals, and R4 is a phenyl or benzyl radical each bearing one or more substituents as defined above for a phenyl radical R , or an acid-addition salt thereof. 3. A composition as claimed in claim 1 wherein, in the triazole derivative, R3 is selected from phenyl, 2-, 3- or 4-chlorophenyl, 2,3- or 2,6-dichlorophenyl, 2-, 3- or 4-fluorophenyl, 2,3- or 2,6-difluorophenyl, 2-, 3- or 4-bromophenyl, 2-chloro-4-fluorophenyl, 2fluoro-4-chlorophenyl, 2-chloro-6-fluorophenyl, 2-, 3or 4-methoxyphenyl, 2,4-dimethoxyphenyl, 2-, 3- or 4ethoxyphenyl, 2-, 3- or 4-nitrophenyl, 2-chloro-4-nitrophenyl, 2-chloro-5-nitrophenyl, 2-, 3- or 4-methylphenyl, 2,4-dimethylphenyl, 2-, 3- or 4-t-butylphenyl, 2-, 3or 4-trifluoromethylphenyl, 2-, 3- or 4-trifluoromethoxyphenyl, 2-, 3- or 4-(1,1,2,2-tetrafluoroethyl)phenyl, 2,3-(difluoromethylenedioxy)-phenyl, 2-fluoro-4-methoxyphenyl, 2-methoxy-4-fluorophenyl, 2-methoxy-4-chlorophenyl, 2-, 3- or 4-phenexyphenyl, 2-, 3- or 4-phenylphenyl (2-, 3- or 4-biphenylyl), 2-, 3- or 4-benzylphenyl, 2-, 3- or 4-benzyloxyphenyl, 2-, 3- or 4-(4-chloro- or 4-fluoro-benzyloxy)phenyl, 2-, 3- or 4-aminophenyl, 2-, 3- or 4-(N,N-dimethylamino)phenyl, 2-, 3- or 4-(methoxy-carbonyl)phenyl and 2-, 3- or 4-morpholinophenyl and R4 is selected from the same radicals, benzyl, a-methylbenzyl and the corresponding ring substituted benzyl and a-methylbenzyl groups, bearing substituents as defined above in R3. 4. A,fungicidal composition for pharmaceutical or veterinary use which comprises a triazole derivative of the fcrmula: EMI20.1 wherein R5 and R6, which may be the same or different, are each a phenyl radical bearing a halogen substituent in the 4-position, or a salt thereof, and an inert carrier or diluent. 5. A composition as claimed in claim 4 wherein in the triazole derivative, the halogen substituent is a chlorine, fluorine or bromine atom. 6. A composition as claimed in claim 4 wherein in the triazole derivative, either or both of R5 and R6 bears one or more additional substituents selected from nitro, cyano, 1-5C alkyl, 1-4C alkoxy, 1-4C halogenoalkyl and 1-4C halogenoalkoxy radicals. 7. A fungicidal composition which comprises 1-(2,4 dichlorophenyl)-l-(4-fluorophenyl)-2-(1,2,4-triazol-1- yl)-ethanol or a salt thereof, and an inert carrier or diluent. 8. A composition as claimed in any preceding claim which is in a form suitable for oral administration to mammals. 9. A method of inhibiting or killing a microorganism of the genus Candida or Trichophyton, which comprises administering a triazole compound of the formula II as defined in claim 1, or a composition as claimed in claim 1, 4 or 7, to the locus of the said miero-organism.

Inventors: PARRY, KEITH PETER, WORTHINGTON, PAUL ANTHONY
Applicants: IMPERIAL CHEMICAL INDUSTRIES PLC
Application year: 1981
Main classification: A61K31
IPC codes: C07D521, A01N43, A61K31, A61P31, C07D405